Medtronic, Itochu invest in 'intelligent medicine'
This article was originally published in Clinica
Executive Summary
Medtech giant Medtronic and Japanese conglomerate Itochu have taken a stake in Proteus Biomedical, a Redwood City, California-based company specialising in in-body electronics and sensor technologies that are then integrated into existing medical devices and pharmaceuticals to improve therapeutic outcomes. Contributions from Medtronic and Itochu helped Proteus raise $32m in a series D equity financing. Proteus' existing shareholders – which include, among others, St Jude Medical, Kaiser Permanente Ventures and various venture capitalists – also injected some funding. This current round will remain open "for a period of time" to additional investors, said Proteus. The firm will use the cash to move its cardiovascular device programmes through development and manufacturing, and advance its cardiovascular pharmaceutical programmes into human clinical trials.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.